Focus Partners Advisor Solutions’s Alnylam Pharmaceuticals ALNY Stock Holding History

Focus Partners Advisor Solutions’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$341K	Sell	1,133 -449	-28%	-$135K	﹤0.01%	953
2026 Q1	$523K	Sell	1,582 -2,513	-61%	-$855K	0.01%	764
2025 Q4	$1.63M	Sell	4,095 -1,032	-20%	-$457K	0.02%	354
2025 Q3	$2.28M	Buy	5,127 +4,317	+533%	+$1.76M	0.03%	306
2025 Q2	$263K	Sell	810 -1,914	-70%	-$530K	﹤0.01%	918
2025 Q1	$736K	Buy	2,724 +1,862	+216%	+$479K	0.01%	464
2024 Q4	$203K	Buy	+862	New	+$227K	﹤0.01%	732

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Focus Partners Advisor Solutions's ALNY Position: Q2 2026 in Review

Focus Partners Advisor Solutions reduced its Alnylam Pharmaceuticals (ALNY) stake by 28% in Q2 2026, selling an estimated $135K and leaving 1,133 shares worth $341K. The position accounts for ﹤0.01% of the portfolio, ranked #953.

Focus Partners Advisor Solutions first reported a position in ALNY in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.28M in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Focus Partners Advisor Solutions held 1,133 shares of Alnylam Pharmaceuticals worth $341K as of Q2 2026.
Focus Partners Advisor Solutions sold 449 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $135K.
Alnylam Pharmaceuticals made up ﹤0.01% of Focus Partners Advisor Solutions's portfolio in Q2 2026, its #953 holding.
Focus Partners Advisor Solutions first reported a position in Alnylam Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
Focus Partners Advisor Solutions's Alnylam Pharmaceuticals position peaked at $2.28M in Q3 2025.
790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Focus Partners Advisor Solutions's 13F filing for Q2 2026, filed 6 Aug 2026.